EB病毒检测在淋巴瘤分型及患者预后判断中的应用  

Application of Epstein-Barr virus detection in judging lymphomaclassification and prognosis of patients

作　　者：吴凤 郑蝶菲 徐卫益[1] WU Feng;ZHENG Diefei;XU Weiyi(Department of Laboratory Medicine,the First Affiliated Hospital,Zhejiang University School of Medicine/Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province/Institute of Laboratory Medicine,Zhejiang University,Hangzhou,Zhejiang 310000,China;Taizhou University,Taizhou,Zhejiang 318000,China)

机构地区：[1]浙江大学医学院附属第一医院检验科/浙江省临床体外诊断技术研究重点实验室/浙江大学检验医学研究所,浙江杭州310000 [2]台州学院,浙江台州318000

出　　处：《现代医药卫生》2025年第3期634-637,共4页Journal of Modern Medicine & Health

摘　　要：目的 通过检测初诊的淋巴瘤患者血液EB病毒(EBV),了解其对淋巴瘤分型及患者预后判断的影响。方法 采用回顾病例资料的方法收集2016年1月1日至2019年8月3日浙江大学医学院附属第一医院收治的363例淋巴瘤患者的分型、分期、EBV拷贝数、影像学资料、实验室生物指标等资料,分析不同类型、阶段淋巴瘤患者EBV感染的差异,以及对预后的影响。结果 363例患者中最常见的分型为弥漫性大B淋巴细胞淋巴瘤,EBV阳性率达30.30%(110/363),既往感染免疫球蛋白G阳性率为98.35%(357/363)。国际预后指数评分0~2分患者EBV阳性率[62.50%(25/40)]与3~5分患者[37.50%(15/40)]比较,Ⅰ~Ⅱ期患者[21.31%(13/61)]EBV阳性率与Ⅲ~Ⅳ期患者[78.69%(48/61)]比较,差异均无统计学意义(P>0.05)。EBV阳性患者治疗前病灶影像学与EBV阴性患者比较,差异无统计学意义(P>0.05)。EBV阳性患者治疗后完全缓解、部分缓解率[13.16%(5/38)、86.94%(33/38)]与EBV阴性患者[45.00%(45/100),55.00%(55/100)]比较,差异均有统计学意义(P<0.05)。结论 淋巴瘤患者进行EBV检测在疾病分型和治疗过程中对疗效和预后判断均具有很好的指导作用。Objective To investigate the effect of Epstein-Barr Virus(EBV)in blood of newly diagnosed lymphoma patients on lymphoma classification and prognosis judgment.Methods The data of 363 lymphoma patients admitted to the First Hospital Affiliated to Zhejiang University School of Medicine from January 1,2016 to August 3,2019 were collected using the method of retrospective case data,including typing,staging,EBV copy number,imaging data,and laboratory bioindicators.The differences of EBV infection in patients with different types and stages of lymphoma were analyzed,and their impact on prognosis was analyzed.Results The most common type of 363 patients was diffuse large B-cell lymphoma,with an EBV-positive rate of 30.30%(110/363),and an immunoglobulin G-positive rate of 98.35%(357/363)for previous infections.There was no significant difference in the positive rate of EBV between patients with international prognosis index score 0-2[62.50%(25/40)]and patients with international prognosis index score 3-5[37.50%(15/40)],or between patients with stageⅠ-Ⅱ[21.31%(13/61)]and patients with stageⅢ-Ⅳ[78.69%(48/61)],the differences were not statistically significant(P>0.05).There was no significant difference in imaging between EBV-positive patients and EBV-negative patients before treatment,the differences were not statistically significant(P>0.05).The complete remission rate and partial remission rate of[13.16%(5/38),86.94%(33/38)]EBV positive patients after treatment were significantly different from those of EBV negative patients[45.00%(45/100),55.00%(55/100)],the difference is statistically significant(P<0.05).Conclusion EBV testing in lymphoma patients has a good guiding role for both efficacy and prognosis during disease classification and treatment.

关 键 词：EB病毒 淋巴瘤 预后 

分 类 号：R733[医药卫生—肿瘤]